Immune Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 16, 2021 at 09:02 am EDT
Share
Immune Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 189,258 compared to USD 18,006 a year ago. Net loss was USD 112,696 compared to USD 803,546 a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 1.76 a year ago. For the half year, operating loss was USD 476,683 compared to USD 413,312 a year ago. Net income was USD 677,705 compared to net loss of USD 1.596 million a year ago. Basic earnings per share from continuing operations was USD 1.41 compared to basic loss per share from continuing operations of USD 3.49 a year ago. Diluted earnings per share from continuing operations was USD 0.05 compared to diluted loss per share from continuing operations of USD 3.49 a year ago.
Biostax Corp. is a developer and marketer of pharmaceutical, biotechnology, and MedTech products. The Company has partnerships in the fields of autoimmunity and immune restoration and are able to deliver solutions today for people that are living with autoimmunity, chronic inflammation, infection, and cancer. Its internal and partner programs comprised of JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) that has demonstrated anti-fibrotic, immuno-modulating, and anti-inflammatory activities in preclinical models; Lodonal, is a once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS), and LDN, which is a compound formula that is purported to provide immune-modulating benefits that include cancer, pain, autoimmune, and anti-aging.
BIOSTAX CORP. 
